Genetec Corp. (4492) AI Stock Analysis

• Market Cap: ¥5.47B
• Dividend Yield: 3.87%
• Average Volume (3M): 44.85K
• Price to Earnings (P/E): 14.0
• Beta (1Y): 0.90
• Revenue Growth: 11.30%
• EPS Growth: -21.37%
• Country: JP
• Employees: 347
• Sector: Technology
• Sector Strength: 94
• Industry: Software - Application
• EPS (TTM): 1.50
• Shares Outstanding: 11,727,700
• 10 Day Avg. Volume: 50,210
• 30 Day Avg. Volume: 44,850
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥523.00
• Price Target Upside: 10.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 75 Outperform
• Price Target: ¥523.00 ▲(10.81% Upside)

Genetec Corp. benefits from strong financial performance and attractive valuation metrics, which are the primary drivers of its score. The technical analysis suggests some caution due to bearish trends, but the stock's valuation and financial health provide a solid foundation for potential growth.

Genetec Corp. Business Overview & Revenue Model

Company Description

Genetec Corp. (4492) is a technology company specializing in the development and manufacturing of advanced electronic and optical components. The company operates within sectors including semiconductor manufacturing, precision equipment, and optical technology. Genetec's core products and services include the production of semiconductor devices, precision measuring instruments, and other related technologies aimed at enhancing efficiency and performance across various industrial applications.

How the Company Makes Money

Genetec Corp. generates revenue primarily through the sale of its semiconductor and optical technology products. The company manufactures and distributes high-performance components that are critical in the production and operation of electronic devices and equipment. Key revenue streams include sales to industrial clients in the technology and electronics sectors, where the demand for precision and efficiency drives the need for Genetec's products. Significant partnerships with leading technology firms and manufacturers amplify its market reach and contribute to its earnings. The company's expertise in innovation and technological advancements positions it as a leader in its field, further stabilizing and growing its revenue base.

Genetec Corp. Financial Statement Overview

Summary

Genetec Corp. is performing well across its financial statements, with strong revenue growth, profitability, and a solid balance sheet with low leverage. While cash flow management shows room for improvement, the overall financial health is robust, indicating positive growth prospects.

Income Statement

Genetec Corp. demonstrates healthy revenue growth, with a notable increase from 2024 to 2025. The gross profit margin is strong at approximately 40%, indicating good cost control relative to revenue. Net profit margin is also healthy at around 5%, showing profitability. However, the EBIT margin is moderate, suggesting room for operational efficiency improvements.

Balance Sheet

The company has a relatively low debt-to-equity ratio, indicating low financial leverage, which is favorable. The return on equity (ROE) is robust, reflecting efficient use of shareholder capital. The equity ratio is stable, suggesting a strong capital base and financial stability.

Cash Flow

Genetec Corp. has shown fluctuations in free cash flow but maintains a positive trajectory. The operating cash flow to net income ratio is positive, indicating efficient cash generation from operations. However, there is room for improvement in free cash flow management.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	8.12B	7.15B	5.86B	4.68B	4.08B
Gross Profit	3.27B	2.91B	2.32B	1.96B	1.56B
EBITDA	829.40M	783.24M	245.09M	153.83M	301.93M
Net Income	421.12M	414.77M	23.76M	56.64M	173.41M
Balance Sheet
Total Assets	7.15B	4.52B	4.12B	3.25B	2.84B
Cash, Cash Equivalents and Short-Term Investments	1.99B	1.17B	1.08B	1.04B	1.48B
Total Debt	2.26B	640.00M	976.09M	50.62M	75.00M
Total Liabilities	4.75B	2.31B	2.26B	1.39B	1.02B
Stockholders Equity	2.40B	2.21B	1.87B	1.86B	1.83B
Cash Flow
Free Cash Flow	384.76M	495.19M	-359.44M	-176.37M	406.28M
Operating Cash Flow	451.42M	602.37M	-223.12M	-24.03M	443.26M
Investing Cash Flow	-388.73M	-55.73M	-439.20M	-98.15M	-38.53M
Financing Cash Flow	655.92M	-410.02M	714.93M	-94.71M	-76.04M

Genetec Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 472.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4492, the sentiment is Negative. The current price of 472 is below the 20-day moving average (MA) of 476.80, above the 50-day MA of 457.50, and below the 200-day MA of 510.52, indicating a neutral trend. The MACD of 7.09 indicates Positive momentum. The RSI at 46.18 is Neutral, neither overbought nor oversold. The STOCH value of 12.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4492.

Genetec Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4060	77 Outperform	¥6.16B	21.16		0.58%	10.95%	39.53%
3841	77 Outperform	¥5.24B	24.98		2.96%	2.53%	-32.88%
4492	75 Outperform	¥5.47B	14.03		3.87%	11.30%	-21.37%
4491	69 Neutral	¥5.79B	14.37		1.74%	7.19%	-2.13%
4829	66 Neutral	¥4.59B	211.41		2.50%	-5.41%	-89.63%
Sector *	61 Neutral	$36.30B	7.26	-7.27%	1.97%	7.74%	-7.92%
2321	47 Neutral	¥10.08B	―		―	-7.41%	74.50%